About: Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD
Creator	Bertz, H Fazekas, T Greinix, H Halter, J Hildebrandt, G Holler, E Lawitschka, A Pavletic, S Wolff, D
source	Medline; PMC
abstract	This consensus statement established under the auspices of the German working group on BM and blood stem cell transplantation (DAG-KBT), the German Society of Hematology and Oncology (DGHO), the Austrian Stem Cell Transplant Working Group, the Swiss Blood Stem Cell Transplantation Group (SBST) and the German-Austrian Pediatric Working Group on SCT (Päd-Ag-KBT) summarizes current evidence for diagnosis, immunosuppressive and supportive therapy to provide practical guidelines for the care and treatment of patients with pulmonary manifestations of chronic GVHD (cGVHD). Pulmonary cGVHD can present with obstructive and/or restrictive changes. Disease severity ranges from subclinical pulmonary function test (PFT) impairment to respiratory insufficiency with bronchiolitis obliterans being the only pulmonary complication currently considered diagnostic of cGVHD. Early diagnosis may improve clinical outcome, and regular post-transplant follow-up PFTs are recommended. Diagnostic work-up includes high-resolution computed tomography, bronchoalveolar lavage and histology. Topical treatment is based on inhalative steroids plus beta-agonists. Early addition of azithromycin is suggested. Systemic first-line treatment consists of corticosteroids plus, if any, continuation of other immunosuppressive therapy. Second-line therapy and beyond includes extracorporeal photopheresis, mammalian target of rapamycin inhibitors, mycophenolate, etanercept, imatinib and TLI, but efficacy is limited. Clinical trials are urgently needed to improve understanding and treatment of this deleterious complication.
has issue date	2011-03-28(xsd:dateTime)
bibo:doi	10.1038/bmt.2011.35
bibo:pmid	21441964
has license	no-cc
sha1sum (hex)	836a3bb211e8e8f40430763b38cd95fc5de14785
schema:url	https://doi.org/10.1038/bmt.2011.35
resource representing a document's title	Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD
has PubMed Central identifier	PMC7094778
has PubMed identifier	21441964
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:836a3bb211e8e8f40430763b38cd95fc5de14785#body_text
is schema:about of	named entity 'DIAGNOSIS' named entity 'CHRONIC GVHD' named entity 'CONFERENCE' named entity 'TREATMENT' named entity 'PULMONARY' named entity 'REPORT' named entity 'CLINICAL PRACTICE' named entity 'CONSENSUS' named entity 'Diagnosis' named entity 'consensus conference' named entity 'GVHD' named entity 'FEV1' named entity 'air trapping' named entity 'productive cough' named entity 'TLC' named entity 'fibrotic' named entity 'clinical symptoms' named entity 'short-acting' named entity 'Bone Marrow Transplantation' named entity 'GVHD' named entity 'HRCT' named entity 'forced expiratory volume' named entity 'general population' named entity 'non-infectious' named entity 'extracorporeal photopheresis' named entity 'American Society of Hematology' named entity 'First-line treatment' named entity 'FVC' named entity 'WBC' named entity 'HRCT' named entity 'FVC' named entity 'FEV1' named entity 'FEV1' named entity 'Haemophilus influenzae' named entity 'FVC' named entity 'serum' named entity 'everolimus' named entity 'FEV1' named entity 'tobramycin' named entity 'clinical trials' named entity 'bacterial infections' named entity 'bronchoconstriction' named entity 'HSCT' named entity 'asymptomatic' named entity 'FVC' named entity 'Extracorporeal photopheresis' named entity 'Mycobaterium tuberculosis' named entity 'short-acting' named entity 'PFT' named entity 'Stem Cell Transplant' named entity 'HSCT' named entity 'GVHD' named entity 'tuberculosis' named entity 'Pulmonary hypertension' named entity 'FEV1' named entity 'lung disease' named entity 'TBI' named entity 'myopathy' named entity 'fluticasone' named entity 'neutrophilic' named entity 'pathophysiologically' named entity 'azithromycin' named entity 'Fever' named entity 'follow-up' named entity 'etanercept' named entity 'clinical trials' named entity 'immunosuppressive treatment' named entity 'pulmonary disease' named entity 'HRCT' named entity 'asthma' named entity 'topical therapy' named entity 'forced expiratory volume' named entity 'HSCT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software